In the second quarter of 2026, Korea's two biggest cosmetics companies both had reasons to smile. LG Household & Health Care's beauty division swung to an operating profit of KRW 44.4 billion (revenue KRW 818.4 billion, +3.9%), and companywide operating profit jumped 87.5% to KRW 102.8 billion. Amorepacific Group also posted revenue of KRW 1,254.3 billion (+14.6%) and operating profit of KRW 122.8 billion (+53.3%), with overseas business especially strong (revenue +28%, operating profit +99%). A year ago, both companies were struggling with slowing Chinese consumption; now they've rebounded together — welcome K-beauty news after a long stretch. But in the same quarter, Pharma Research's cosmetics exports rose 124%, and Hugel's cosmetics revenue climbed 32.8%. Even with mainstream K-beauty back on its feet, it still hasn't caught up to dermocosmetics' pace of growth. Dig into that gap, and something more interesting turns up — neither Amorepacific nor LG Household & Health Care built its dermocosmetics business from scratch by itself. Both entered by acquiring brands rooted in pharmaceutical companies and dermatology clinics.
Where Dermocosmetics Comes From — It Was Never Just "Cosmetics," It Was Always "Between Medicine and Cosmetics"
Dermocosmetic is a portmanteau of "dermatology" and "cosmetic." The concept emerged in the European pharmaceutical industry in the early 1900s to describe products sitting between ordinary cosmetics and topical medicine — from the start, its identity was never "cosmetics made by a cosmetics company," but "cosmetics that passed through the hands of doctors and pharmacists." France's pharmacy-brand cosmetics are the classic originators. Vichy was developed by a medical doctor based on his own experience of a wound healing in thermal spring water in 1931. Avène traces back to the skin-soothing properties of spring water that had passed through groundwater for more than 40 years since 1736. La Roche-Posay likewise built its identity on thermal spring water and became a brand recommended and stocked by dermatologists. All three still treat pharmacy and dermatology-clinic channels as their core distribution today.
Korea's dermocosmetics lineage traces a strikingly similar pattern. Dongkook Pharmaceutical's Centellian24, considered Korea's first-generation dermocosmetics brand, is a pharmaceutical company product. Daewoong Pharmaceutical's Easydew is among the oldest of the pharma-company dermocosmetics brands, built around DW-EGF (99% purity), the world's first commercialized patented ingredient of its kind — it reached KRW 100 billion in annual sales ahead of schedule in September 2025. Ildong Pharmaceutical joined the same category with its pharmacy-exclusive brand Rejunic, and Chong Kun Dang followed in 2021 with Dr.CureVell, built around a natural-ingredient concept. Gowoonsesang Cosmetics' Dr.G was founded by dermatologist Dr. Ahn Gun-young, who opened Gowoonsesang Dermatology Clinic in Seoul's Donam-dong in 1998, then established the company in 2000 and launched the brand in 2003. More recently, the fast-growing Rejuran Cosmetic from Pharma Research and Wellage/Vaironback from Hugel are both cases of companies that made filler and regenerative-medicine materials extending that ingredient technology into cosmetics. Botulinum toxin maker Medytox runs Neuraderm, built on its own anti-aging technology platform, M.Biome, and Jetema — which has long developed and manufactured its own fillers — recently joined the same category by strengthening its cosmetics business.
What's notable is that even Amorepacific and LG Household & Health Care never escaped this pattern. Amorepacific's dermocosmetics brand ESTRA (globally branded AESTURA) carries the heritage of its former affiliate Tae Pacific Pharmaceutical, which was absorbed into Amorepacific and converted into a division in June 2021. LG Household & Health Care only entered the dermocosmetics market at the end of 2014, by acquiring CNP (Cha & Park Cosmetics), founded by a dermatologist couple. Neither company built its dermocosmetics brand in-house through its main beauty R&D organization — both instead acquired a separate entity that already carried pharmaceutical or medical DNA. That says dermocosmetics is a market that can't be entered through brand marketing alone — it requires a different kind of asset altogether: clinical evidence and a medical-institution distribution network.
Key Insight — Production and Distribution Are Designed Differently From the Start
The real difference between mainstream K-beauty and dermocosmetics isn't marketing copy — it's baked into how the products are made and sold.
Production: Mainstream K-beauty brands like Sulwhasoo, Hera, and Innisfree are developed by combining ingredients to fit trends and maximizing sensory polish — texture, scent, packaging. Dermocosmetics, by contrast, typically inherits its parent company's pharmaceutical and medical-device production infrastructure and ingredient technology wholesale. Pharma Research uses c-PDRN — the same core substance, PDRN, used in its facial-wrinkle-improvement medical device Rejuran, purified through its proprietary DOT (DNA Optimizing Technology) patent — directly as a cosmetics ingredient. Hugel applies "Real HA," a high-purity hyaluronic acid ingredient "purified through a process equivalent to pharmaceutical-grade refining," to its cosmetics line. In other words, these companies aren't running ingredients out of a cosmetics lab — they're running them "downstream" out of a filler or regenerative-medicine lab into a cosmetics line. That's also why they can present clinical data and human-trial evidence alongside their products.
Distribution: This is where a common misconception creeps in — there's no such thing as a dermocosmetic that requires a prescription to buy. Under Korea's Cosmetics Act, the moment a product requires a prescription, it's legally classified as a drug rather than a cosmetic — so no dermocosmetic can ever require a pharmacist's or doctor's prescription. The distinction that actually exists is who handles the product. One track is "clinic-exclusive" lines that hospitals and clinics recommend alongside treatment or sell only in-house; the other is "general retail" lines sold without any prescription or consultation, available through pharmacies, H&B stores, or online to anyone. Medytox's Neuraderm shows this structure clearly — it was designed from the outset with a separate "Clinic Derma" line sold only through hospitals and clinics, and a "Basic Derma" line with reduced irritants formulated for general consumers. Dermocosmetics has long treated pharmacy, dermatology, and clinic channels as its core, and has only recently begun expanding into H&B (health and beauty) stores like Olive Young. The industry calls this a "two-track strategy" — supplying an accessible general-retail line to mass channels, and a more concentrated, functionally stronger clinic-exclusive line to pharmacies and clinics, separately. Lately, a new format has emerged too — "beauty-specialized pharmacies" that go beyond dispensing medicine and specialize in curating dermocosmetics. Mainstream K-beauty brands, in contrast, are designed from the start around mass marketing that mobilizes department stores, roadshops, duty-free stores, global retail, and online e-commerce all at once. Both sit under the same broad category of "cosmetics," but dermocosmetics is built to start in B2B (medical institutions) and expand into B2C — distribution running in reverse — while mainstream K-beauty assumes mass B2C distribution from day one. The business design itself is different.
Business Impact — A Gap That Widens Even in a Quarter When Everyone Did Well
Q2 2026 was a strong quarter for K-beauty broadly — which is exactly why dermocosmetics' pace of growth stands out even more. Pharma Research posted Q2 cosmetics (Rejuran Cosmetic) revenue of KRW 60.2 billion — domestic sales of KRW 16.6 billion (+47%) and exports of KRW 43.6 billion (+124%), with overseas sales more than doubling. Companywide Q2 revenue reached KRW 178.7 billion (+27%) and operating profit KRW 66.5 billion (+19%), both quarterly records, with first-half cumulative figures of KRW 324.8 billion in revenue (+26%) and KRW 123.8 billion in operating profit (+23%) — also first-half records. Hugel's Q2 cosmetics and other-segment revenue rose 32.8% to KRW 19.8 billion, with first-half cumulative revenue at KRW 39.0 billion (+31.7%). Companywide first-half revenue also hit a record KRW 254.5 billion (+27.2%), though operating profit (KRW 103.7 billion, +8.4%) grew more modestly than revenue — the company attributed this to upfront investment costs tied to building out its U.S. direct-sales operation. Dongkook Pharmaceutical's Centellian24 has grown revenue every year — KRW 154.9 billion in 2023, KRW 181.5 billion in 2024, KRW 222.7 billion in 2025 — and Q1 2026 exports surged 332% year over year, with securities firms (LS Securities) projecting full-year 2026 revenue of KRW 293.0 billion (+31.6%).
LG Household & Health Care and Amorepacific's rebounds tell a different kind of story. LG Household & Health Care's beauty division posted Q2 revenue of KRW 818.4 billion (+3.9%) and swung to an operating profit of KRW 44.4 billion, with North American revenue surpassing Chinese revenue for the first time ever — a sign of the company shifting its axis away from China dependence toward the West. Amorepacific Group's overseas business also drove its rebound, with revenue up 28% and operating profit up 99%. Both are genuinely welcome recoveries, but their growth rates still fall well short of Pharma Research's export growth (+124%) or Hugel's cosmetics growth (+32.8%). In the end, what Q2 2026 shows is that mainstream K-beauty's rebound is a recovery-type story — bouncing back by shifting its axis from China to the West — while dermocosmetics is growing structurally faster, regardless of the broader market cycle.
✦RIT's Insights
What strikes RIT most looking at this landscape is that Amorepacific and LG Household & Health Care — two companies with arguably the strongest R&D and marketing organizations in Korean beauty — both chose "acquisition" over "in-house development" when it came to dermocosmetics. That says the core asset in this market isn't brand power or marketing budget. Clinical data, hospital and clinic distribution networks, and trust built with medical professionals aren't things money can buy quickly — they're assets accumulated over a long time, which is exactly why both conglomerates chose to buy, whole, companies that already had them. Anyone running new-business efforts at a major cosmetics company should sit with this precedent — this isn't a market you can enter simply by expanding a brand-marketing organization, so M&A or securing a license may actually be a faster path in than building in-house. Conversely, executives at pharma, biotech, or medical-device companies can read the same lesson in reverse: the strategy of extending filler or regenerative-medicine materials into cosmetics is already validated by Pharma Research and Hugel, but downstreaming ingredient technology into cosmetics and building consumer-facing brand and distribution capability are entirely different challenges that need to be weighed together.
Q2 2026's results confirm that read once more. Until last year, the narrative could have been "dermocosmetics benefits while mainstream struggles in China." But this quarter, both LG Household & Health Care and Amorepacific rebounded — decisively enough that North America overtook China for the first time. And yet Pharma Research's cosmetics exports still rose 124%. A spillover narrative can't explain that gap. Dermocosmetics' growth isn't riding on mainstream's weakness — it's tracing its own, steeper trajectory independently. In RIT's view, this is exactly the point investors and analysts miss when they lump the cosmetics sector together under the single label "K-beauty." The gap kept widening even in a quarter as broadly strong as Q2 2026, so mainstream brands and dermocosmetics are more accurately evaluated as separate tracks.
What's worth watching going forward is whether this dynamic could reverse. Companies like Pharma Research and Hugel, which started out in hospital and clinic channels, are moving into mass channels like Olive Young at an accelerating pace — and if they build up mass-marketing capability to match, they could start eating into mainstream K-beauty's own territory. Right now the framing is "pharma and medical companies eyeing the cosmetics market"; a few years from now, it may be worth keeping in mind that the framing could flip to "dermatology-derived brands becoming K-beauty's mainstream." Pharma Research's cosmetics exports (+124%) and Centellian24's export growth (+332% in Q1) also show these companies expanding overseas first, wielding clinical and regulatory-approval data as their weapon. Anyone in export or global business should note that companies able to share the clinical data needed for country-specific cosmetics approvals (EU CPNP, U.S. FDA registration, and the like) across their medical-device or pharmaceutical divisions tend to expand overseas faster. That said, just as Hugel's Q2 operating profit didn't grow in step with its revenue increase (+25.1% revenue, operating profit roughly flat year over year), rising marketing and distribution investment costs as these companies move into mass channels are a growth pain none of them can avoid — also worth keeping in view.
Where this distribution reshuffle is actually colliding in practice shows up more concretely in recent moves by duty-free stores and department stores. They've been trying harder to bring large beauty-specialized pharmacy chains directly into their stores, and in practice this runs into two structural problems. One is a lineup problem: whether a pharmacist is stationed on-site or not determines what kinds of dermocosmetics a store can even carry, so the type of pharmacy format brought in decides the breadth of brands available from the start. The second is the fee structure: pharmacies must operate under fixed rent rather than revenue-linked fees, which clashes with the revenue-share model department stores and duty-free operators are used to. Conversely, if a duty-free operator buys and resells dermocosmetics directly on a wholesale basis, it can collect revenue-linked fees — but then the range of brands it can carry narrows. In the end, it's a trade-off between a broad lineup and revenue-linked fees that can't be had simultaneously. Anyone doing MD work at Olive Young, a pharmacy chain, or a duty-free operator needs to negotiate product assortment and pricing separately by channel, on the assumption that this two-track distribution is here to stay. How to resolve this trade-off remains the most practical challenge in duty-free and department stores' current push to bring dermocosmetics in-house.
Sources
- [Q2 2026 Results] Amorepacific Group's operating profit up 53% YoY to KRW 122.8bn (Inthenews, Q2 2026 results, overseas revenue and operating profit)
- LG H&H's Q2 operating profit tops KRW 100bn — North America sales overtake China for the first time (Asia Economy Daily, 2026-07-29, the beauty division's return to profit and North America revenue)
- Pharma Research rides the "Rejuran" export wave to its best-ever Q2 (Dealsite, Pharma Research's Q2 cosmetics revenue and export growth rate)
- Hugel posts H1 revenue of KRW 254.5bn, operating profit KRW 103.7bn — "a record" (Money Today, 2026-08-06, Hugel's cosmetics division revenue and H1 results)
- Dongkook Pharmaceutical's Centellian24 exports up 332% — nears the KRW 1tn club (Hankyung, 2026-05-17, Centellian24's FY2023–2025 revenue and export growth)
- LG H&H's CNP Cosmetics M&A — "a stroke of genius" (Dealsite, background on the 2014 acquisition of CNP/Dr. Chahn & Dr. Park)
- Amorepacific resolves to absorb group affiliate AESTURA (Amorepacific official, 2021-06-22)
- DART electronic disclosure system (dart.fss.or.kr) — Amorepacific Group, LG H&H, Pharma Research, Hugel, and Dongkook Pharmaceutical's 2026 quarterly reports (cited by name where a specific filing URL could not be pinpointed)
